Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2

Brian M. Alexander, Patrick Y. Wen, Lorenzo Trippa, David A. Reardon, Wai Kwan Alfred Yung, Giovanni Parmigiani, Donald A. Berry

Research output: Contribution to journalArticle

Abstract

The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory studies, potentially related to a lack of efficient control arms or the use of unvalidated surrogate endpoints. Streamlining clinical trials and providing a flexible infrastructure for biomarker development is clearly needed for patients with glioblastoma. The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology.

Original languageEnglish (US)
Pages (from-to)972-978
Number of pages7
JournalNeuro-Oncology
Volume15
Issue number8
DOIs
StatePublished - Aug 2013
Externally publishedYes

Fingerprint

Glioblastoma
Biomarkers
Clinical Trials
Breast Neoplasms
Therapeutics

Keywords

  • adaptive
  • Bayesian
  • biomarker
  • clinical trials
  • glioblastoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Alexander, B. M., Wen, P. Y., Trippa, L., Reardon, D. A., Yung, W. K. A., Parmigiani, G., & Berry, D. A. (2013). Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2. Neuro-Oncology, 15(8), 972-978. https://doi.org/10.1093/neuonc/not088

Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2. / Alexander, Brian M.; Wen, Patrick Y.; Trippa, Lorenzo; Reardon, David A.; Yung, Wai Kwan Alfred; Parmigiani, Giovanni; Berry, Donald A.

In: Neuro-Oncology, Vol. 15, No. 8, 08.2013, p. 972-978.

Research output: Contribution to journalArticle

Alexander, BM, Wen, PY, Trippa, L, Reardon, DA, Yung, WKA, Parmigiani, G & Berry, DA 2013, 'Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2', Neuro-Oncology, vol. 15, no. 8, pp. 972-978. https://doi.org/10.1093/neuonc/not088
Alexander BM, Wen PY, Trippa L, Reardon DA, Yung WKA, Parmigiani G et al. Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2. Neuro-Oncology. 2013 Aug;15(8):972-978. https://doi.org/10.1093/neuonc/not088
Alexander, Brian M. ; Wen, Patrick Y. ; Trippa, Lorenzo ; Reardon, David A. ; Yung, Wai Kwan Alfred ; Parmigiani, Giovanni ; Berry, Donald A. / Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2. In: Neuro-Oncology. 2013 ; Vol. 15, No. 8. pp. 972-978.
@article{a1f7e19143024e568e17d582d5f099ca,
title = "Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2",
abstract = "The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory studies, potentially related to a lack of efficient control arms or the use of unvalidated surrogate endpoints. Streamlining clinical trials and providing a flexible infrastructure for biomarker development is clearly needed for patients with glioblastoma. The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology.",
keywords = "adaptive, Bayesian, biomarker, clinical trials, glioblastoma",
author = "Alexander, {Brian M.} and Wen, {Patrick Y.} and Lorenzo Trippa and Reardon, {David A.} and Yung, {Wai Kwan Alfred} and Giovanni Parmigiani and Berry, {Donald A.}",
year = "2013",
month = "8",
doi = "10.1093/neuonc/not088",
language = "English (US)",
volume = "15",
pages = "972--978",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2

AU - Alexander, Brian M.

AU - Wen, Patrick Y.

AU - Trippa, Lorenzo

AU - Reardon, David A.

AU - Yung, Wai Kwan Alfred

AU - Parmigiani, Giovanni

AU - Berry, Donald A.

PY - 2013/8

Y1 - 2013/8

N2 - The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory studies, potentially related to a lack of efficient control arms or the use of unvalidated surrogate endpoints. Streamlining clinical trials and providing a flexible infrastructure for biomarker development is clearly needed for patients with glioblastoma. The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology.

AB - The traditional clinical trials infrastructure may not be ideally suited to evaluate the numerous therapeutic hypotheses that result from the increasing number of available targeted agents combined with the various methodologies to molecularly subclassify patients with glioblastoma. Additionally, results from smaller screening studies are rarely translated to successful larger confirmatory studies, potentially related to a lack of efficient control arms or the use of unvalidated surrogate endpoints. Streamlining clinical trials and providing a flexible infrastructure for biomarker development is clearly needed for patients with glioblastoma. The experience developing and implementing the I-SPY studies in breast cancer may serve as a guide to developing such trials in neuro-oncology.

KW - adaptive

KW - Bayesian

KW - biomarker

KW - clinical trials

KW - glioblastoma

UR - http://www.scopus.com/inward/record.url?scp=84880694475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880694475&partnerID=8YFLogxK

U2 - 10.1093/neuonc/not088

DO - 10.1093/neuonc/not088

M3 - Article

VL - 15

SP - 972

EP - 978

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 8

ER -